var WiderPlanetAdRendererVar = { type : "script", passback : '/images/common/pc_view_banner.jpg', category : "pc_view_banner", width : "468", height : "60", zoneid : "30713", targetid : "kb_pc_view_ad" };
Lee Won-sik, CEO of Idience, stated, "This project is a groundbreaking attempt to expand PARP inhibitors as ADC payloads based on combination therapy clinical data," and added, "We expect this to be an opportunity to secure differentiated candidate substances and technological competitiveness in the global ADC market."

Han Tae-dong, CEO of Aptis, expressed, "We hope that the synergy created by combining Aptis's proprietary ADC-related technologies and platforms with Idience's anticancer drug pipeline will become a turning point in opening a new chapter in the development of next-generation dual payload ADCs."

Popular News